

Detailed contents

Acknowledgements *xxiii*
Contributors *xxv*
Symbols and abbreviations *xxvii*

| | |
|--|-----------|
| 1 Clinical approach | 1 |
| History taking in patients with haematological disease | 2 |
| Physical examination | 4 |
| Splenomegaly | 5 |
| Lymphadenopathy | 6 |
| Unexplained anaemia | 8 |
| Patient with elevated haemoglobin | 10 |
| Elevated WBC | 12 |
| Reduced WBC | 14 |
| Elevated platelet count | 16 |
| Reduced platelet count | 18 |
| Easy bruising | 20 |
| Recurrent thromboembolism | 22 |
| Pathological fracture | 23 |
| Raised ESR | 24 |
| Serum or urine paraprotein | 25 |
| Anaemia in pregnancy | 26 |
| Thrombocytopenia in pregnancy | 27 |
| Prolonged bleeding after surgery | 28 |
| Positive sickle test (HbS solubility test) | 30 |
| 2 Red cell disorders | 31 |
| The peripheral blood film in anaemias | 32 |
| Anaemia in renal disease | 34 |
| Anaemia in endocrine disease | 36 |
| Anaemia in joint disease | 38 |
| Anaemia in gastrointestinal disease | 40 |
| Anaemia in liver disease | 41 |
| Iron (Fe) deficiency anaemia | 42 |

xii DETAILED CONTENTS

Vitamin B₁₂ deficiency 46
Folate deficiency 48
Other causes of megaloblastic anaemia 50
Anaemia in other deficiency states 51
Haemolytic syndromes 52
Genetic control of haemoglobin production 54
Sickling disorders 56
HbS—new therapies 60
Sickle cell trait (HbAS) 62
Other sickling disorders 63
Other haemoglobinopathies 64
Unstable haemoglobins 66
Thalassaemias 68
α thalassaemia 69
β thalassaemia 70
Other thalassaemias 74
Hereditary persistence of fetal haemoglobin 75
Hb patterns in haemoglobin disorders 76
Non-immune haemolysis 78
Hereditary spherocytosis 80
Hereditary elliptocytosis 83
Glucose-6-phosphate dehydrogenase (G6PD) deficiency 84
Pyruvate kinase (PK) deficiency 87
Other red cell enzymopathies 88
Drug-induced haemolytic anaemia 90
Methaemoglobinaemia 91
Microangiopathic haemolytic anaemia (MAHA) 92
Acanthocytosis 93
Autoimmune haemolytic anaemia 94
Cold haemagglutinin disease (CHAD) 96
Leucoerythroblastic anaemia 97
Aplastic anaemia 98
Paroxysmal nocturnal haemoglobinuria 100
Pure red cell aplasia 102
Iron (Fe) overload 103
Transfusion haemosiderosis 106

| | |
|---|------------|
| 3 White blood cell abnormalities | 109 |
| Neutrophilia | 110 |
| Neutropenia | 112 |
| Lymphocytosis and lymphopenia | 114 |
| Eosinophilia | 115 |
| Basophilia and basopenia | 116 |
| Monocytosis and monocytopenia | 117 |
| Mononucleosis syndromes | 118 |

| | |
|---|------------|
| 4 Leukaemia | 119 |
| Acute myeloblastic leukaemia (AML) | 120 |
| Acute lymphoblastic leukaemia (ALL) | 132 |
| Chronic myeloid leukaemia (CML) | 140 |
| Chronic lymphocytic leukaemia (B-CLL) | 150 |
| Cell markers in chronic lymphoproliferative disorders | 158 |
| Prolymphocytic leukaemia (PLL) | 160 |
| Hairy cell leukaemia and variant | 162 |
| Splenic marginal zone lymphoma (SMZL) | 166 |
| Mantle cell lymphoma (MCL) | 168 |
| Large granular lymphocyte leukaemia (LGLL) | 172 |
| Adult T-cell leukaemia-lymphoma (ATL) | 176 |
| Sézary syndrome (SS) | 178 |

| | |
|---|------------|
| 5 Lymphoma | 179 |
| Non-Hodgkin lymphoma (NHL) | 180 |
| Indolent lymphoma | 186 |
| Treatment of indolent lymphoma | 188 |
| Aggressive lymphomas | 194 |
| Initial treatment of aggressive lymphomas | 196 |
| CNS lymphoma | 204 |
| Hodgkin lymphoma (HL, Hodgkin's disease) | 206 |

| | |
|---------------------------------|------------|
| 6 Myelodysplasia | 221 |
| Myelodysplastic syndromes (MDS) | 222 |
| Classification | 224 |
| Clinical features of MDS | 228 |

xiv DETAILED CONTENTS

Diagnostic criteria of MDS 232
Prognostic factors in MDS 234
Clinical variants of MDS 236
Management of MDS 238
Response criteria 244
Myelodysplastic/myeloproliferative diseases (MDS/MPD) 248

7 Myeloproliferative neoplasms (MPNs) 253

Myeloproliferative neoplasms (MPNs) 254
Pathogenesis of the MPNs 256
Polycythaemia vera (PV) 260
Natural history of PV 266
Management of PV 268
Secondary erythrocytosis 272
Relative erythrocytosis (RE) 273
Idiopathic erythrocytosis (IE) 274
Essential thrombocythaemia (ET) 276
Reactive thrombocytosis (RT) 285
Primary myelofibrosis (PMF) 286
Chronic neutrophilic leukaemia (CNL) 298
Chronic eosinophilic leukaemia (CEL) and idiopathic
hypereosinophilic syndrome (HES) 300
Mast cell disease (mastocytosis) 306
Systemic mastocytosis (SM) 310
MPNs-unclassifiable (MPN-U) 317

8 Paraproteinaemias 319

Paraproteinaemias 320
Monoclonal gammopathy of undetermined
significance (MGUS) 322
Smouldering multiple myeloma (syn. asymptomatic
myeloma) 326
Multiple myeloma (MM) 330
Variant forms of myeloma 359
Cryoglobulinaemia 360
POEMS syndrome 362
Plasmacytoma 364

Waldenström macroglobulinaemia (WM) 366

Heavy chain disease (HCD) 378

AL (1° systemic) amyloidosis 380

9 Haematopoietic stem cell transplantation (SCT) 387

Haemopoietic stem cell transplantation (SCT) 388

Indications for haemopoietic SCT 392

Allogeneic SCT 396

Autologous SCT 399

Investigations for BMT/PBSCT 400

Pretransplant investigation of donors 402

Bone marrow harvesting 404

Peripheral blood stem cell mobilization and harvesting 406

Microbiological screening for stem cell cryopreservation 408

Stem cell transplant conditioning regimens 410

Infusion of cryopreserved stem cells 412

Infusion of fresh non-cryopreserved stem cells 414

Blood product support for SCT 416

GvHD prophylaxis 420

Acute GvHD 424

Chronic GvHD 428

Veno-occlusive disease (syn. sinusoidal obstruction syndrome) 432

Invasive fungal infections and antifungal therapy 436

CMV prophylaxis and treatment 440

Post-transplant vaccination programme 442

Treatment of relapse post-allogeneic SCT 444

Discharge and follow-up 445

10 Haemostasis and thrombosis 447

Assessing haemostasis 448

The coagulation system 450

Laboratory tests 452

Platelets 456

Bleeding 460

Bleeding: laboratory investigations 463

Bleeding: therapeutic products 464

| | |
|--|-----|
| von Willebrand disease (vWD) | 466 |
| Haemophilia A and B | 470 |
| Rare congenital coagulation disorders | 476 |
| Congenital thrombocytopenias | 479 |
| Congenital platelet function defects | 480 |
| Congenital vascular disorders | 481 |
| Haemorrhagic disease of the newborn | 482 |
| Thrombocytopenia (acquired) | 484 |
| Specific thrombocytopenic syndromes | 486 |
| Disseminated intravascular coagulation (DIC) | 488 |
| Anticoagulant drug therapy | 490 |
| Liver disease | 492 |
| Renal disease | 494 |
| Acquired anticoagulants and inhibitors | 495 |
| Treatment of spontaneous FVIII inhibitor | 496 |
| Acquired disorders of platelet function | 498 |
| Henoch–Schönlein purpura | 500 |
| Peri-operative bleeding and massive blood loss | 502 |
| Massive blood loss | 504 |
| Heparin | 506 |
| Heparin induced thrombocytopenia/ with thrombosis (HIT/T) | 508 |
| Oral anticoagulant therapy (warfarin, VKAs) | 510 |
| Thrombosis | 514 |
| Risk assessment and thromboprophylaxis | 520 |
| Example of VTE Risk Assessment | 524 |
| Heritable thrombophilia | 526 |
| Acquired thrombophilia | 530 |
| Thrombotic thrombocytopenic purpura (TTP) | 534 |
| Haemolytic uraemic syndrome (HUS) | 536 |
| Heparin-induced thrombocytopenia (HIT) | 538 |

11 Immunodeficiency**541**

| | |
|---------------------------------------|-----|
| Congenital immunodeficiency syndromes | 542 |
| Acquired immune deficiencies | 546 |
| HIV infection and AIDS | 548 |
| Therapy of HIV infection | 552 |

| | |
|--|------------|
| 12 Paediatric haematology | 555 |
| Blood counts in children | 556 |
| Red cell transfusion and blood component therapy—special considerations in neonates and children | 558 |
| Polycythaemia in newborn and childhood | 562 |
| Neonatal anaemia | 564 |
| Anaemia of prematurity | 566 |
| Haemolytic anaemia in the neonate | 568 |
| Congenital red cell defects | 570 |
| Acquired red cell defects | 572 |
| Haemolytic disease of the newborn (HDN) | 574 |
| Hyperbilirubinaemia | 578 |
| Neonatal haemostasis | 580 |
| Neonatal alloimmune thrombocytopenia (NAIT) | 582 |
| Congenital dyserythropoietic anaemias | 584 |
| Congenital red cell aplasia | 586 |
| Acquired red cell aplasia | 588 |
| Fanconi anaemia (FA) | 590 |
| Rare congenital marrow failure syndromes | 592 |
| Neutropenia in childhood | 596 |
| Disorders of neutrophil function | 598 |
| Childhood immune (idiopathic) thrombocytopenic purpura (ITP) | 600 |
| Haemolytic uraemic syndrome (HUS) | 602 |
| Childhood cancer and malignant blood disorders | 604 |
| Childhood lymphoblastic leukaemia | 608 |
| Childhood lymphomas | 612 |
| Childhood acute myeloid leukaemia (AML) | 616 |
| Childhood myelodysplastic syndromes and chronic leukaemias | 620 |
| Histiocytic syndromes | 624 |
| Haematological effects of systemic disease in children | 628 |
| 13 Haematological emergencies | 631 |
| Septic shock/neutropenic fever | 632 |
| Transfusion reactions | 634 |

xviii DETAILED CONTENTS

Immediate-type hypersensitivity reactions 636
Febrile transfusion reactions 636
Delayed transfusion reaction 636
Bacterial contamination of blood products 637
Post-transfusion purpura 637
Hypercalcaemia 638
Hyperviscosity 640
Disseminated intravascular coagulation (DIC) 642
Overdosage of thrombolytic therapy 645
Heparin overdosage 646
Heparin-induced thrombocytopenia (HIT) 648
Warfarin overdosage 650
Massive blood transfusion 652
Paraparesis/spinal collapse 654
Leucostasis 655
Thrombotic thrombocytopenic purpura 656
Sickle crisis 658

14 Supportive care 659

Quality of life 660
Pain management 662
Psychological support 665

15 Protocols and procedures 667

Acute leukaemia—investigations 668
Platelet storage and administration 670
Platelet reactions and refractoriness 672
Prophylactic regimen for neutropenic patients 674
Guidelines for use of IV antibiotics in neutropenic patients 676
Treatment of neutropenic sepsis when source unknown 678
Treatment of neutropenic sepsis when source
known/suspected 680
Prophylaxis for patients treated with purine analogues 682
Tumour lysis syndrome (TLS) 684
Management of chronic bone marrow failure 686
Venepuncture 688
Venesection 689

| | |
|---|-----|
| Tunnelled central venous catheters | 690 |
| Bone marrow examination | 692 |
| Administration of chemotherapy | 694 |
| Antiemetics for chemotherapy | 696 |
| Intrathecal chemotherapy | 698 |
| Management of extravasation | 700 |
| Specific procedures following extravasation | 702 |
| Splenectomy | 704 |
| Plasma exchange (plasmapheresis) | 706 |
| Leucapheresis | 712 |
| Anticoagulation therapy—heparin | 710 |
| Oral anticoagulation | 712 |
| Management of needlestick injuries | 714 |
| Chemotherapy protocols: | |
| ABVD | 716 |
| BEACOPP & Escalated BEACOPP | 717 |
| BEAM | 718 |
| CHOP 21 & CHOP 14 | 720 |
| ChIVPP | 722 |
| CODOX-M/IVAC | 724 |
| CTD & CTDa | 727 |
| DHAP ± R | 728 |
| EPOCH & DA-EPOCH ± R | 729 |
| ESHAP ± R | 730 |
| FC ± R | 732 |
| FMD ± R (FND ± R) | 733 |
| Hyper-CVAD ± R / MA ± R | 734 |
| ICE ± R | 736 |
| MCP ± R | 737 |
| MINE | 738 |
| Mini-BEAM ± R | 739 |
| R-CHOP | 740 |
| R-CVP & CVP | 741 |
| Rituximab | 742 |
| Stanford V | 744 |
| VAPEC-B | 746 |

| | |
|---|------------|
| 16 Haematological investigations | 747 |
| Full blood count | 748 |
| Blood film | 748 |
| Plasma viscosity | 748 |
| ESR | 749 |
| Haematinic assays | 749 |
| Haemoglobin electrophoresis | 749 |
| Haptoglobin | 750 |
| Schumm's test | 750 |
| Kleihauer test | 750 |
| Reticulocytes | 751 |
| Urinary haemosiderin | 752 |
| Ham's test | 753 |
| Immunophenotyping | 754 |
| Cytogenetics | 756 |
| Human leucocyte antigen (HLA) typing | 758 |

| | |
|--|------------|
| 17 Blood transfusion | 761 |
| Introduction | 762 |
| Using the blood transfusion laboratory | 764 |
| Transfusion of red blood cells | 766 |
| Platelet transfusion | 768 |
| Fresh frozen plasma (FFP) | 770 |
| Cryoprecipitate | 772 |
| Intravenous immunoglobulin (IVIg) | 774 |
| Transfusion transmitted infections (TTI) | 776 |
| TRALI and TA-GVHD | 778 |
| Irradiated and CMV-negative blood products | 779 |
| Autologous blood transfusion | 780 |
| Maximum surgical blood ordering schedule (MSBOS) | 782 |
| Jehovah's Witnesses | 784 |

| | |
|--|------------|
| 18 Phone numbers and addresses | 787 |
| American Society of Hematology | 788 |
| Birmingham Clinical Trials Unit (BCTU) | 788 |
| British Society for Haematology | 788 |

| | |
|--|------------|
| CancerBACUP | 789 |
| CTSU | 789 |
| European Hematology Association | 790 |
| Leukaemia Research Fund (LRF) | 790 |
| Medical Research Council | 791 |
| National Cancer Research Network | 791 |
| Northern and Yorkshire Clinical Trials and Research Unit | 791 |
| <hr/> | |
| 19 Haematology online | 793 |
| Haematology online | 794 |
| <hr/> | |
| 20 Charts and nomograms | 801 |
| Karnofsky performance status | 802 |
| WHO/ECOG performance status | 802 |
| WHO haematological toxicity scale | 803 |
| Body surface area nomogram | 804 |
| Gentamicin dosage nomogram | 805 |
| The Sokal Score for CML prognostic groups | 806 |
| <hr/> | |
| 21 Normal ranges | 807 |
| Adult normal ranges | 808 |
| Paediatric normal ranges | 810 |
| Index | 811 |